dr. reck on the rationale of the impower150 trial in nsclc
Published 6 years ago • 224 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
2:09
dr. reck on the impower150 study
-
1:55
dr. langer on the impower150 trial in nsclc
-
1:18
dr. reck on the safety of pembrolizumab in keynote-024 in metastatic nsclc
-
5:15
metastatic nsclc: a look at the impower150 trial
-
1:39
dr. sequist on implications of the impower150 trial in advanced nonsquamous nsclc
-
1:05
dr. brahmer on the impower150 trial in nsclc
-
6:51
impower150: implications for the treatment of nsclc
-
1:31
impower150: efficacy outcomes of atezolizumab addition in pre-treated egfr-mutated nsclc
-
3:28
advanced-stage nondriver nsclc: impower150 trial
-
5:08
the impower150 regimen
-
3:13
howard (jack) west, md, discusses key takeaways from the impower150 study in nsclc
-
5:55
impower-150: egfr-mutated subset analysis
-
3:18
looking at the impower data in nsclc
-
3:11
impower150: atezolizumab, chemotherapy and bevacizumab for nsclc
-
1:08
dr. horn on the fda approval of atezolizumab plus bevacizumab and chemotherapy in nsclc
-
3:05
managing the impower 150 regimen in nonsquamous mnsclc
-
1:33
real-world experience of impower150 regimen for egfr nsclc
-
8:08
quadruplet therapy in nsclc: impower150
-
11:28
atezolizumab in first line nsclc: early clinical results from the impower150 trial (bmic-020)